A149300 Stock Overview
Engages in the development and commercialization of solutions for the bio and medical industries in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Apures Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩399.00 |
| 52 Week High | ₩610.00 |
| 52 Week Low | ₩266.00 |
| Beta | 0 |
| 11 Month Change | 19.46% |
| 3 Month Change | 22.39% |
| 1 Year Change | -25.97% |
| 33 Year Change | -78.37% |
| 5 Year Change | -80.05% |
| Change since IPO | -84.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| A149300 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -6.8% | -5.8% | -2.8% |
| 1Y | -26.0% | 28.2% | -3.4% |
Return vs Industry: A149300 underperformed the KR Biotechs industry which returned 28.2% over the past year.
Return vs Market: A149300 underperformed the KR Market which returned -3.4% over the past year.
Price Volatility
| A149300 volatility | |
|---|---|
| A149300 Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A149300's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A149300's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Choi Sundeok | www.apures.com |
Apures Co., Ltd. engages in the development and commercialization of solutions for the bio and medical industries in South Korea. It is involved in the development of MICROPIG, which are research and laboratory mini pig species to provide solutions through standardization of biomaterials for medical experiments and development of regenerative medicine treatments, including cell therapy and heterogeneous organs. The company provides Porcine Primary Cell for in vitro test; and heterogeneous organ technology, a technology that develops and transplants animal tissues and organs to replace human tissues and organs.
Apures Co., Ltd. Fundamentals Summary
| A149300 fundamental statistics | |
|---|---|
| Market cap | ₩11.07b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A149300 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A149300 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A149300 perform over the long term?
See historical performance and comparison